Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 12;13(22):6793.
doi: 10.3390/jcm13226793.

Diagnosis and Treatment of Renal ANCA Vasculitis: A Summary of the Consensus Document of the Catalan Group for the Study of Glomerular Diseases (GLOMCAT)

Juliana Bordignon Draibe  1 , Helena Marco  2 , Meritxell Ibernon  3 , Irene Agraz  4 , Carola Arcal  5 , Xoana Barros  2 , Victoria Cabrera  6 , Iara Da Silva  7 , Montserrat Díaz  2 , Xavier Fulladosa  1 , Elena Guillén  8 , Patricia Lescano  6 , Laura Martínez Valenzuela  1 , Eva Márquez  9 , Nadia Martín  10 , Ana Merino  10 , Maru Navarro  3 , Eva Rodríguez  9 , Mª José Soler  4 , Joan Torras  1 , Luís F Quintana  8 , On Behalf Of The Catalan Society Of Nephrology
Affiliations
Review

Diagnosis and Treatment of Renal ANCA Vasculitis: A Summary of the Consensus Document of the Catalan Group for the Study of Glomerular Diseases (GLOMCAT)

Juliana Bordignon Draibe et al. J Clin Med. .

Abstract

The document provides a comprehensive overview of the diagnosis, monitoring, and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) with renal involvement, focusing on granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It outlines the definitions, clinical presentation, histopathological classification, monitoring strategies, induction and maintenance treatments, as well as special considerations for relapsing, refractory, and frail patients with renal AAV. The document was prepared by the Catalan Group for the Study of Glomerular Diseases (GLOMCAT), which comprises nephrologists with extensive experience in the diagnosis and treatment of AAV patients. Several virtual and face-to-face meetings were held for coordination, section assignments, and content discussion. An exhaustive and systematic search of the literature was carried out, which included, among others, the following databases: PubMed, EMBASE, Cochrane Library, Google Scholar, and ClinicalTrials.gov, as well as the abstract books of national and international congresses. Overall, the document provides a comprehensive guide for clinicians managing patients with renal AAV, offering evidence-based recommendations for diagnosis, monitoring, and treatment across various clinical scenarios.

Keywords: anti-neutrophil cytoplasmic antibody-associated vasculitis; eosinophilic granulomatosis with polyangiitis; granulomatosis with polyangiitis; microscopic polyangiitis.

PubMed Disclaimer

Conflict of interest statement

Meritxell Ibernon fees from Astra-Zeneca, Boehringer-Ingelheim and Astellas. Elena Guillen received consultant honoraria from CSL Vifor. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Clinical manifestations of ANCA-associated renal vasculitis. CNS: central nervous system; CVA: cerebrovascular accident. (Figure adapted from Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology 2022, 1–17. [7]).
Figure 2
Figure 2
Renal Risk Score.
Figure 3
Figure 3
Berden’s histopathologic classification in AAV.
Figure 4
Figure 4
AAV Monitoring algorithm.
Figure 5
Figure 5
Algorithm Renal ANCA VASCULITIS.
Figure 5
Figure 5
Algorithm Renal ANCA VASCULITIS.
Figure 6
Figure 6
Algorithm to treat renal ANCA vasculitis relapses.
Figure 7
Figure 7
Renal ANCA Vasculitis in frail patients.
See this image and copyright information in PMC

References

    1. Geetha D., Jefferson J.A. ANCA-associated vasculitis: Core currículum. Am. J. Kidney Dis. 2020;75:124–137. doi: 10.1053/j.ajkd.2019.04.031. - DOI - PubMed
    1. Jayne D.R.W., Merkel P.A., Schall T.J., Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N. Engl. J. Med. 2021;384:599–609. doi: 10.1056/NEJMoa2023386. - DOI - PubMed
    1. McAdoo S.P., Medjeral-Thomas N., Gopaluni S., Tanna A., Mansfield N., Galliford J., Griffith M., Levy J., Cairns T.D., Jayne D., et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol. Dial. Transplant. 2019;34:63–73. doi: 10.1093/ndt/gfx378. - DOI - PMC - PubMed
    1. Hellmich B., Sanchez-Alamo B., Schirmer J.H., Berti A., Blockmans D., Cid M.C., Holle J.U., Hollinger N., Karadag O., Kronbichler A., et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 2023;83:30–47. doi: 10.1136/ard-2022-223764. - DOI - PubMed
    1. Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P., Savage C., Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM Int. J. Med. 1994;87:671–678. - PubMed

LinkOut - more resources